Biotech Venture Funding Sees Second Quarter Rebound


NVCALast week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of 2013.  The report, which is prepared by NVCA and PriceWaterhouseCoopers LLP using data from Thomson Reuters, indicates that venture capitalists invested $6.7 billion in 913 deals in the second quarter, which constituted a 12% increase in dollars and a 2% increase in deals as compared with the first quarter, when $6.0 billion was invested in 896 deals (see chart below, which shows total venture funding from the second quarter of 2009, when the Great Recession ended through the second quarter of 2013; data from MoneyTree Reports; click on chart to expand).

Venture Funding - Q2 2009 to Q2 2013

Venture Funding_no title
The biotechnology sector rebounded in the second quarter to place second behind the software sector, with funding increasing by 41% to $1.3 billion and the number of deals rising by 2% to 103.  The software sector once again took the top spot inPricewaterhouseCoopers (PWC) funding -- with $2.1 billion invested -- marking the fifth straight quarter in which the software sector topped the $2 billion funding level (see chart below, which shows venture funding for the biotech (blue), medicial devices (red), and software (green) sectors since the third quarter of 2009, which was the last quarter in which the biotech sector outpaced the software industry; data from MoneyTree Reports; click on chart to expand).  Medical Device investment dropped by 1% with respect to both dollars and deals, with $543 million being invested in 71 deals.  Overall, eight of the seventeen sectors tracked by the NVCA saw decreases in dollars invested in the second quarter.

Venture Funding by Industry - Q3 2009 to Q2 2013

VF by Industry_no titleBiotechnology funding = blue; Medical devices = red; Software = green

Thomson ReutersWith respect to the second quarter results, NVCA president Mark Heesen observed that "[i]n many ways it feels like the late 1990's with information technology driving venture investment and significantly outpacing other sectors when it comes to level of activity and momentum."  He also noted that "[l]ife sciences investment is poised for a slow and steady recovery, provided we can continue to see progress on the regulatory front."

For additional information regarding this and other related topics, please see:

• "Biotech Venture Funding Down 33% in First Quarter," April 30, 2013
• "Annual Venture Funding Drops for First Time in Three Years," February 4, 2013
• "Biotech Venture Funding Up 64% in Third Quarter," October 29, 2012
• "Venture Funding in Life Sciences Sector Drops 9% in Second Quarter," July 22, 2012
• "Biotech Venture Funding Drops 43% in First Quarter," May 3, 2012
• "Venture Funding Increased 22% in 2011," February 2, 2012
• "Life Sciences Venture Funding Drops in Third Quarter," October 27, 2011
• "Life Sciences Venture Funding up 37% in Second Quarter," August 1, 2011
• "VentureSource Reports 35% Increase in 1Q Venture Funding," April 26, 2011
• "NVCA Reports Modest Gains in First Quarter Venture Funding," April 19, 2011?
• "NVCA Reports 31% Drop in Venture Funding for Third Quarter," October 17, 2010?
• "NVCA Reports 34% Increase in Venture Funding for Second Quarter," July 22, 2010?
• "NVCA Report Shows First Quarter Drop in Venture Funding," April 20, 2010?
• "Biotech/Pharma Financing Improving, R&D Spending Up," August 31, 2009
• "NVCA Study Shows Increase in Third Quarter Venture Funding," October 23, 2009?
• "First Quarter Venture Capital Funding at 12-Year Low," April 23, 2009?
• "NVCA Study Shows Decline in 2008 Investment; BIO Study Predicts Biotech Rebound in 2009," February 16, 2009


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:


McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.